

HIPRAVIAR-B1 lyophilisate for ocular suspension/use in drinking water for chickens

Authorised

- Newcastle disease virus, strain B1 Hitchner, Live

Product identification

Medicine name:

HIPRAVIAR-B1 lyophilisate for ocular suspension/use in drinking water for chickens

Active substance:

Newcastle disease virus, strain B1 Hitchner, Live

Target species:

Chicken (broiler)

Chicken (pullet for egg production, future layer)

Future breeder pullet

Route of administration:

Nebulisation use

In drinking water use

Ocular use

Product details

Active substance and strength:

Newcastle disease virus, strain B1 Hitchner, Live
5011870000.00 50% Embryo Infective Dose / 1.00 Dose

Pharmaceutical form:

Lyophilisate for ocularnasal suspension/use in drinking water

Withdrawal period by route of administration:

Nebulisation use:

-

Chicken (broiler)

- Meat and offal. 0 day

-

Chicken (pullet for egg production, future layer)

- Meat and offal. 0 day

-

Future breeder pullet

- Meat and offal. 0 day

In drinking water use:

-

Chicken (broiler)

- Meat and offal. 0 day

-

Chicken (pullet for egg production, future layer)

- Meat and offal. 0 day

-

Future breeder pullet

- Meat and offal. 0 day

Ocularnasal use:

-

Chicken (broiler)

- Meat and offal. 0 day

-

Chicken (pullet for egg production, future layer)

- Meat and offal. 0 day

-

Future breeder pullet

- Meat and offal. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI01AD06

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Germany

Package description:

box containing 10 vials of 1000 doses + box containing 10 bottles of solvent

box containing 10 vials of 5000 doses

box containing 10 vials of 2500 doses

box containing 10 vials of 1000 doses

box containing 10 vials of 500 doses

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Laboratorios Hipra S.A.

Marketing authorisation date:

9/01/2017

Manufacturing sites for batch release:

Laboratorios Hipra S.A.

Responsible authority:

Paul-Ehrlich-Institut

Authorisation number:

PEI.V.11884.01.1

Date of authorisation status change:

18/10/2021

Reference member state:

Spain

Procedure number:

ES/V/0275/001

Concerned member states:

Germany

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

Package Leaflet

Labelling

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.

eu-PUAR-hipraviar-b1-en.pdf